News | Mammography | November 21, 2018

Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA

Company will show off cloud-based quantitative breast imaging analysis tools, host speaker series

Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA

November 21, 2018 — Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. 25–30 in Chicago. Its suite of cloud-based quantitative breast imaging analysis tools is designed to help maintain consistent quality in breast screening.

This year, Volpara will launch the VolparaLive! system, mammography's first real-time decision support system at the point of care. The VolparaLive! system automatically analyzes patient positioning and compression to help technologists acquire consistent, high-quality mammograms. One of the key benefits of the system is the cost reduction of fewer technical recalls, made possible by providing technologists with actionable data before the patient leaves the room.

Major improvements to the VolparaEnterprise software will be demonstrated for the first time:

  • A new reporting function for periodic image quality reviews further streamlines Enhancing Quality Using the Inspection Program (EQUIP) compliance and the image quality review process;
  • Users can generate a list of exams based on the VolparaEnterprise quality assessment for periodic image quality reviews, sorting by interpreting physicians and technologists; and
  • The software now features vPGMI, a new image positioning quality standard, according to Volpara.

This year, Volpara will host a distinguished speaker series at RSNA, including:

  • Prof. Jack Cuzick: Volpara and Risk Assessment: Importance of Volumetric Density in TC8
    • Director, Wolfson Institute of Preventive Medicine; Head, Centre for Cancer Prevention and John Snow Professor of Epidemiology, Queen Mary University of London
  • JoAnn Pushkin: Breast Density Legislation and Education – US and Europe
    • Executive Director, DenseBreast-Info.org
  • Prof. Sir Mike Brady: How AI and Machine Learning Can Impact Mammography
    • Professor of Oncological Imaging, University of Oxford
  • Amy Chatten, MPH, Measuring the Impact of Hands-On Technologist Training on Mammographic Image Quality
    • Executive Director, Mammography Educators, LLC

 

For more information: www.volparasolutions.com

Related Content

Low-dose #CT #lung #scans are used to #screen for #lung_cancer in high-risk people such as heavy #smokers

Getty Images

News | Lung Imaging | April 16, 2021
April 17, 2021 — A deep learning algorithm accurately predicts the risk of death from...
#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F